A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

January 31, 2027

Conditions
ObesityOverweight
Interventions
DRUG

Bimagrumab

Administered SC

DRUG

Tirzepatide

Administered SC

DRUG

Bimagrumab Placebo

Administered SC

DRUG

Tirzepatide Placebo

Administered SC

Trial Locations (12)

19462

Keystone Clinical Studies, Plymouth Meeting

32256

Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville

33135

Suncoast Research Group, Miami

33461

Altus Research, Lake Worth

35205

Central Research Associates, Birmingham

36207

Pinnacle Research Group, LLC, Anniston

39157

SKY Integrative Medical Center/SKYCRNG, Ridgeland

60640

Great Lakes Clinical Trials - Ravenswood, Chicago

94598

Diablo Clinical Research, Inc., Walnut Creek

96814

East-West Medical Research Institute, Honolulu

98052

Eastside Research Associates, Redmond

98057

Rainier Clinical Research Center, Renton

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY